Literature DB >> 16507387

Oligosaccharide structures of von Willebrand factor and their potential role in von Willebrand disease.

Carolyn M Millar1, Simon A Brown.   

Abstract

Oligosaccharides make up approximately 20% of the mass of VWF and although their structures are well established, their functional role remains unclear. Modification of the VWF oligosaccharide structures has been shown to result in increased plasma clearance of the protein. A mutation which alters cell type-specific expression of the Galgt2 glycosyltransferase gene in the RIIIS/J mouse results in an autosomal dominant partial quantitative deficiency of VWF. Increased plasma clearance of VWF has been demonstrated in some individuals with a partial quantitative deficiency of the protein and it is possible that variation in VWF glycosylation may contribute towards this. ABH antigens occur within the oligosaccharide component of VWF and may account for the variation in plasma VWF:Ag levels observed between individuals of different ABO blood groups. The structures and functional roles of the oligosaccharide side chains of VWF and possible pathogenetic mechanisms by which they may contribute towards VWD are reviewed in this article.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16507387     DOI: 10.1016/j.blre.2005.02.002

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  9 in total

1.  The origin and function of platelet glycosyltransferases.

Authors:  Hans H Wandall; Viktoria Rumjantseva; Anne Louise Tølbøll Sørensen; Sunita Patel-Hett; Emma C Josefsson; Eric P Bennett; Joseph E Italiano; Henrik Clausen; John H Hartwig; Karin M Hoffmeister
Journal:  Blood       Date:  2012-05-21       Impact factor: 22.113

2.  Circulating but not immobilized N-deglycosylated von Willebrand factor increases platelet adhesion under flow conditions.

Authors:  M A Fallah; V Huck; V Niemeyer; A Desch; J I Angerer; T A J McKinnon; A Wixforth; S W Schneider; M F Schneider
Journal:  Biomicrofluidics       Date:  2013-08-26       Impact factor: 2.800

3.  Glycosylation sterically inhibits platelet adhesion to von Willebrand factor without altering intrinsic conformational dynamics.

Authors:  Alexander Tischer; Venkata R Machha; Laurie Moon-Tasson; Linda M Benson; Matthew Auton
Journal:  J Thromb Haemost       Date:  2019-09-03       Impact factor: 5.824

4.  VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.

Authors:  Jeroen Eikenboom; Augusto B Federici; Richard J Dirven; Giancarlo Castaman; Francesco Rodeghiero; Ulrich Budde; Reinhard Schneppenheim; Javier Batlle; Maria Teresa Canciani; Jenny Goudemand; Ian Peake; Anne Goodeve
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

5.  Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers.

Authors:  Marika Pikta; Galina Zemtsovskaja; Hector Bautista; Georges Nouadje; Timea Szanto; Margus Viigimaa; Valdas Banys
Journal:  J Clin Lab Anal       Date:  2018-02-17       Impact factor: 2.352

6.  Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes.

Authors:  Anne Louise Sørensen; Viktoria Rumjantseva; Sara Nayeb-Hashemi; Henrik Clausen; John H Hartwig; Hans H Wandall; Karin M Hoffmeister
Journal:  Blood       Date:  2009-06-11       Impact factor: 22.113

Review 7.  The molecular genetics of von Willebrand disease.

Authors:  Ergül Berber
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831

8.  [The function and clinical value of Von Willebrand factor propeptide].

Authors:  Jie Yin; Changgeng Ruan
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-10

Review 9.  Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence.

Authors:  Nina Buchtele; Michael Schwameis; James C Gilbert; Christian Schörgenhofer; Bernd Jilma
Journal:  Thromb Haemost       Date:  2018-05-30       Impact factor: 5.249

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.